GNI Group Ltd. (TYO:2160)

Japan flag Japan · Delayed Price · Currency is JPY
2,984.00
-16.00 (-0.53%)
May 12, 2026, 3:30 PM JST
Market Cap166.37B +80.6%
Revenue (ttm)26.84B +13.7%
Net Income-4.24B
EPS-80.90
Shares Out55.75M
PE Ration/a
Forward PE60.04
Dividendn/a
Ex-Dividend Daten/a
Volume620,100
Average Volume847,370
Open2,973.00
Previous Close3,000.00
Day's Range2,953.00 - 3,050.00
52-Week Range2,112.00 - 4,410.00
Betan/a
RSI44.79
Earnings DateMay 15, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic ne... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 990
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 2160
Full Company Profile

Financial Performance

Financial Statements